Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients

Transplantation

Volumn 92, Issue 4, 2011, Pages 477-485

  Wolf, Thomas ^a,b   Oumeraci, Tonio ^a   Gottlieb, Jens ^a   Pich, Andreas ^a   Brors, Benedikt ^b   Eils, Roland ^b,c   Haverich, Axel ^a   Schlegelberger, Brigitte ^a   Welte, Tobias ^a   Zapatka, Marc ^b   Von Neuhoff, Nils ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bronchiolitis obliterans syndrome; Bronchoalveolar lavage fluid; Clinical proteomics; Data mining; Lung transplantation

Indexed keywords

CALGRANULIN A; CLARA CELL PROTEIN; COMPLEMENT COMPONENT C3; DEFENSIN; DEFENSIN 1; DEFENSIN 2; HEMOGLOBIN; HEMOGLOBIN B; HISTATIN; HISTATIN 3; PREALBUMIN; PROTEIN PRECURSOR; SERUM ALBUMIN; SP A1 PRECURSOR; TRANSTHYRETIN CHAIN A; UNCLASSIFIED DRUG; VIMENTIN;

ACUTE GRAFT REJECTION; ADULT; ANALYTIC METHOD; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS SYNDROME; BRONCHOSCOPY; CLINICAL CLASSIFICATION; DECISION TREE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; IN GEL DIGESTION; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATIENT MONITORING; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ADULT; ALPHA-DEFENSINS; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; CALGRANULIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTATINS; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEOME; PROTEOMICS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYNDROME; UTEROGLOBIN;

EID: 80051781151     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318224c109     Document Type: Article

References (46)

1. Robertson AGN, Griffin SM, Murphy DM, et al. Targeting allograft injury and inflammation in the managment of post-lung transplant bronchiolitis obliterans syndrome. Am J Transplant 2009;9:1272.
2. Gottlieb J. Update on lung transplantation. Ther Adv Respir Dis 2008;2:237.
3. Gottlieb J, Welte T, Hoper MM, et al. Lung transplantation. Possibilities and limitations. Internist (Berl) 2004;45:1246.
4. Christie JD, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008;27:957.
5. Riise GC, Williams A, Kjellström C, et al. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998;12:82.
6. Zheng L, Whitford HM, Orsida B, et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant 2006;6:599.
7. Ward C, Walters EH, Zheng L, et al. Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients. Eur Respir J 2002;19:472.
8. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, et al. Circulating and intrapulmonary C-reactive protein: A predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. J Heart Lung Transplant 2009;28:799.
9. Hardison MT, Galin FS, Calderon CE, et al. The presence of a matrixderived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 2009;182:4423.
10. Nelsestuen GL, Martinez MB, Hertz MI, et al. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 2005;5:1705.
11. Zhang Y, Wroblewski M, Hertz MI, et al. Analysis of chronic lung transplant rejection by MALDI-TOF profiles of bronchoalveolar lavage fluid. Proteomics 2006;6:1001.
12. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148.
13. McWilliams TJ, Williams TJ, Whitford HM, et al. Surveillance bronchoscopy in lung transplant recipients: Risk versus benefit. J Heart Lung Transplant 2008;27:1203.
14. Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9:2424.
15. Borrebaeck CA, Wingren C. Transferring proteomic discoveries into clinical practice. Expert Rev Proteomics 2009;6:11.
16. Newton DA, Rao KM, Dluhy RA, et al. Hemoglobin is expressed by alveolar epithelial cells. J Biol Chem 2006;281:5668.
17. Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005;5:2972.
18. Chang DW, Hayashi S, Gharib SA, et al. Proteomic and computational analysis of bronchoalveolar proteins during the course of the acute respiratory distress syndrome. Am J Respir Crit Care Med 2008;178:701.
19. Ishikawa N, Ohlmeier S, Salmenkivi K, et al. Hemoglobin a and/3 are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD. Respir Res 2010;11:123.
20. Skawran B, Dierich M, Steinemann D, et al. Bronchial epithelial cells as a new source for differential transcriptome analysis after lung transplantation. Eur J Cardiothorac Surg 2009;36:715.
21. Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003;284:C2.
22. Kavanagh K, Dowd S. Histatins: Antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004;56:285.
23. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009;9:1903.
24. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008;85:771.
25. Soehnlein O, Lindbom L. Neutrophil-derived azurocidin alarms the immune system. J Leukoc Biol 2009;85:344.
26. Anderson RL, Hiemstra PS, Ward C, et al. Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Eur Respir J 2008;32:670.
27. Griffiths MJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet 2005;366:249.
28. Mahesh B, Leong HS, Nair KS, et al. Autoimmunityto vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 2010;90:4.
29. Borthwick LA, Parker SM, Brougham KA, et al. Epithelialtomesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax 2009;64:770.
30. Mendez MG, Kojima S, Goldman RD. Vimentin induces changesincell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010;24:1838.
31. Nord M, Schubert K, Cassel TN, et al. Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophiliainlung transplant recipients. Transplantation 2002;73:1264.
32. Magi B, Bargagli E, Bini L, et al. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006;6:6354.
33. Paantjens AW, Otten HG, van Ginkel WG, et al. Clara cell secretory protein and surfactant protein-D do not predict bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2010;90:340.
34. Kriegova E, Melle C, Kolek V, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2006;173:1145.
35. Pilette C, Godding V, Kiss R, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:185.
36. Spencer LT, Paone G, Krein PM, et al. Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol 2004;286:L514.
37. Shestakova T, Zhuravel E, Bolgova L, et al. Expression of human betadefensins-1, 2 and 4 mRNA in human lung tumor tissue: A pilot study. Exp Oncol 2008;30:153.
38. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167.
39. Tiroke AH, Bewig B, Haverich A. Bronchoalveolar lavage in lung transplantation. State of the art. Clin Transplant 1999;13:131.
40. Haslam PL, Baughman RP. Report of ERS Task Force: Guidelines for measurementof acellular components and standardization of BAL. Eur Respir J 1999;14:245.
41. Li X, Gentleman R, Lu X, et al. SELDI-TOF mass spectrometry protein data. In: Gentleman R, Carey V, Huber W, et al., eds. Bioinformatics and computational biology solutions using R and Bioconductor. New York, Springer-Verlag 2005, p 91.
42. Jolliffe IT. Principal component analysis. New York, Springer-Verlag 1986.
43. Breitling R, Armengaud P, Amtmann A, et al. Rank products: Asimple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004;573:83.
44. Breiman LE. Random forests. Mach Learn 2001;45:5.
45. Sing T, Sander O, Beerenwinkel N, et al. ROCR: Visualizing classifier performance in R. Bioinformatics 2005;21:3940.
46. Le Bihan MC, Hou Y, Harris N, et al. Proteomic analysis of fast and slow muscles from normal and kyphoscoliotic mice using protein arrays, 2-DE and MS. Proteomics 2006;6:4646.